MASS-C Study: CDC Multistate Assessment of SARS-CoV-2 Seroprevalence (Commercial Labs)

The Centers for Disease Control and Prevention (CDC) requires one or more new contracts for a repeat, cross-sectional, serologic survey using convenience samples collected from commercial laboratories across the United States. The primary purpose of Multistate Assessment of SARS-CoV-2 Seroprevalence in Commercial Laboratory Survey (MASS-C) is to estimate the proportion of people that have been infected by or vaccinated for SARS-CoV-2 during the ongoing epidemic over time, nationally and by geographic location and demographic subcategory. CDC anticipates that there will continue to be a special priority on infection and case rates among children, and therefore, proposes a sampling frame for children with specimens collected over 8-week time periods. 

CDC's work in this contract will use Offeror(s) residual/remnant/excess, deidentified blood specimens to obtain laboratory testing toward determining U.S. seroprevalence by geographic region, pediatric age group, and time period. Offeror(s)  will identify excess, remnant, or residual blood specimens from remaining volumes of previously obtained blood specimens for non-COVID-19 diagnostic or antibody testing. For all 50 states, the District of Columbia and Puerto Rico, monthly commercial lab residual sera samples will be collected, distributed by age category, and tested for both qualitative SARS-CoV-2 nucleocapsid antibodies and quantitative IgG anti-spike antibodies. More specifically, Oferror(s) will collect and test mass amounts of specimens for CLIA-approved and/or EUA-approved ELISA, COVID-19 IgG and/or IgM serological assays, as well as reflexive microneutralization testing for specimens that are seropositive by qualitative anti-nucleocapsid assay if possible. Offeror(s) will provide CDC with data reports of aggregate findings after every 8-week collection/testing period, in addition to a final report at the end of the award performance period. Offerors may propose on any or all of the required tests. This contract is anticipated to be for a base period of eleven (11) months, with one option period of twelve (12) months. 

See Request for Proposal (RFP), *Solicitation Amendment*, and Attachments below for full details.

• Questions Due: January 6, 2022 at 5:00 PM EST to Liz Cole-Greenblatt via email at QST7@cdc.gov. Questions must be submitted in “Attachment D – Q&A Template.”
• Proposals Due: January 24, 2022 at 5:00 PM EST to Liz Cole-Greenblatt via email at QST7@cdc.gov. Late proposals will not be accepted.

*UPDATED (1/12/2022):

Nine (9) questions were submitted regarding this posting. Please see new excel sheet below for vendor questions and CDC responses. 

An amendment has been made to Section D - Performance Work Statement ("PWS") of the solicitation. This amendment edits the language of Task 2.1, removing the requirement to perform reflexive testing "within 5 days" after quantative assay testing. Please see Solictation Amendment document below for revised language clarifying CDC's expectations in Task 2.1.

The Centers for Disease Control and Prevention (CDC) requires one or more new contracts for a repeat, cross-sectional, serologic survey using convenience samples collected from commercial laboratories across the United States. The primary purpose of Multistate Assessment of SARS-CoV-2 Seroprevalence in Commercial Laboratory Survey (MASS-C) is to estimate the proportion of people that have been infected by or vaccinated for SARS-CoV-2 during the ongoing epidemic over time, nationally and by geographic location and demographic subcategory. CDC anticipates that there will continue to be a special priority on infection and case rates among children, and therefore, proposes a sampling frame for children with specimens collected over 8-week time periods. 

CDC's work in this contract will use Offeror(s) residual/remnant/excess, deidentified blood specimens to obtain laboratory testing toward determining U.S. seroprevalence by geographic region, pediatric age group, and time period. Offeror(s)  will identify excess, remnant, or residual blood specimens from remaining volumes of previously obtained blood specimens for non-COVID-19 diagnostic or antibody testing. For all 50 states, the District of Columbia and Puerto Rico, monthly commercial lab residual sera samples will be collected, distributed by age category, and tested for both qualitative SARS-CoV-2 nucleocapsid antibodies and quantitative IgG anti-spike antibodies. More specifically, Oferror(s) will collect and test mass amounts of specimens for CLIA-approved and/or EUA-approved ELISA, COVID-19 IgG and/or IgM serological assays, as well as reflexive microneutralization testing for specimens that are seropositive by qualitative anti-nucleocapsid assay if possible. Offeror(s) will provide CDC with data reports of aggregate findings after every 8-week collection/testing period, in addition to a final report at the end of the award performance period. Offerors may propose on any or all of the required tests. This contract is anticipated to be for a base period of eleven (11) months, with one option period of twelve (12) months. 

See Request for Proposal (RFP) and Attachments below for full details.

Questions Due: January 6, 2022 at 5:00 PM EST to Liz Cole-Greenblatt via email at QST7@cdc.gov. Questions must be submitted in “Attachment D – Q&A Template.”

Proposals Due: January 24, 2022 at 5:00 PM EST to Liz Cole-Greenblatt via email at QST7@cdc.gov. Late proposals will not be accepted.